Published in Vaccine Weekly, April 3rd, 2002
Smith's team has previously shown that low daily doses of the T cell growth factor IL2 can result in accelerated improvement of the immune system when given to individuals with chronic HIV infection. Now, the team is testing whether it is possible to generate protective immunity to HIV, so that antiviral drugs will no longer be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.